Please login to the form below
Zenopa delivers Communiqué prizes to winners
Publicis Resolute's Georgina Chan, MGP's Peter Sayer and Celgene's Sara Jones win the prizes
Roche wins FDA breakthrough for Gazyva in lupus nephritis
Drug originally approved as a lymphoma treatment
Biogen loses another pipeline drug to toxicity concerns
Follows discontinuation of Eisai-partnered Alzheimer's drug
FDA starts speedy review of Merck’s Ebola vaccine
First company to file for approval in the US
Purdue Pharma files for bankruptcy after opioid settlement
Company has faced brunt of blame for fuelling epidemic
Novartis eyes potential new indication for Cosentyx
Unveils positive late-stage results in axial spondyloarthritis
Acceleron scraps rare muscular dystrophy drug
Clinical profile not strong enough to push into late-stage testing
J&J's Tremfya filed for approval in US for psoriatic arthritis
Seeking share of increasingly competitive psoriasis market
New data backs GeNeuro’s MS drug after Servier exit
Search continues for new development partner
Q&A: Jessica Pacey
PME interviews the founder and chief executive of newly launched health comms agency, 67health
-
Who's calling the shots in European healthcare?Patients versus Pharma: industry too powerful, and too cosy with EMA, says Yannis Natsis
-
Q&A with Tim CockroftPME interviews the founding director of akt health communications
-
Envision Pharma Group relocates to support expansionOffice moves in the US prompted by significant growth
-
Biogen and Eisai drop Alzheimer’s drug elenbecestatLatest blow in string of failures for BACE inhibitor category
-
Aimmune gets FDA panel backing for peanut allergy therapyStep closer to becoming first approved treatment
-
FDA fast-tracks AstraZeneca’s Farxiga in heart failure Races to become first-in-class
-
Lundbeck bolts on migraine drug via $1.95bn deal to buy AlderContinues to bulk up its pipeline
-
AbbVie/Allergan's merger faces public opposition Advocacy groups and unions in the US express concerns
-
Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial Regulatory filings expected in first half of 2020
Latest appointments
-
Life announces two new hiresStrenghtens growing creative department
-
New hires at Bayer, Eisai and Accord HealthcareThe latest movers in pharma
-
New faces at 90TEN, Lucid Group and Porterhouse Latest movers in healthcare comms
-
Senior leadership moves announced at Publicis HealthNew roles will support European operations
-
Lucid Group announces new hires at its creative and digital agency Bluedog Follows group's success at Communiqué 2019
Featured jobs
-
Events Executive
-
DOE
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Account Manager – Healthcare advertising
-
Salary TBC
-
Account Director – UK Office
-
Excellent salary and benefits
- Client Services Director- Flexible Working
-
Negotiable
Subscribe to our email news alerts
- Novartis eyes potential new indication for Cosentyx
- J&J's Tremfya filed for approval in US for psoriatic arthritis
- Gracell reports impressive data with one-day CAR-T for leukaemia
- Lucid Group increases footprint in UK, Asia Pacific and Middle East with the acquisition of HealthCare21
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Gracell reports impressive data with one-day CAR-T for leukaemia
- Pharma industry consensus: fix data strategy before pushing artificial intelligence and machine learning applications
- Zenopa delivers Communiqué prizes to winners
- Detecting Alzheimer’s ahead of a cure
- When it’s OK to not be OK: Bedrock breaks down mental health stigma
- Roche wins FDA breakthrough for Gazyva in lupus nephritis
- Programmatic methodology and why you should be using it
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....
Latest intelligence
- Detecting Alzheimer’s ahead of a cure
- A focus on promising new research...
- Programmatic methodology and why you should be using it
- What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
- Can you survive without the blue dot?
- Or has the digital world has replaced our brain...
Quick links
Infographics
